- Read the article on page 340.
- Take the test, recording your answers in the test answers section (Section B) of the CE enrollment form. Each question has only one correct answer.
- Complete registration information (Section A) and course evaluation (Section C).
- Mail completed test with registration fee to: Lippincott Williams & Wilkins, CE Group, 333 7th Ave, 19th Floor, New York, NY 10001.
- Within 4–6 weeks after your CE enrollment form is received, you will be notified of your test results.
- If you pass, you will receive a certificate of earned contact hours and answer key. If you fail, you have the option of taking the test again at no additional cost.
- A passing score for this test is 10 correct answers.
- Need CE STAT? Visit www.nursingcenter.com for immediate results, other CE activities and your personalized CE planner tool.
- No Internet access? Call 800-933-6525, x6617 or x6621, for other rush service options.
- Questions? Contact Lippincott Williams & Wilkins: (646) 674-6617 or (646) 674-6621.
Registration Deadline: October 31, 2007
Provider Accreditation: This Continuing Nursing Education (CNE) activity for 4.0 contact hours is provided by Lippincott Williams & Wilkins, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation and by the American Association of Critical-Care Nurses (AACN 00012278, CERP Category A). This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 4.0 contact hours. LWW is also an approved provider of CNE in Alabama, Florida, and Iowa and holds the following provider numbers: AL, #ABNP0114, FL #FBN2454, IA #75. All of its home study activities are classified for Texas nursing continuing education requirements as Type 1.
Your certificate is valid in all states. This means that your certificate of earned contact hours is valid no matter where you live.
Payment and Discounts:
- The registration fee for this test is $27.00.
- If you take two or more tests in any nursing journal published by LWW and send in your CE enrollment forms together, you may deduct $0.75 from the price of each test.
- We offer special discounts for as few as six tests and institutional bulk discounts for multiple tests. Call (800) 933-6525, x6617 or x6621, for more information.
CE Test Questions
GENERAL PURPOSE: To provide registered professional nurses with the latest research findings on differences between men and women with regard to the prevalence, causes, diagnosis, treatment, and outcomes of coronary artery disease (CAD).
LEARNING OBJECTIVES: After reading this article and taking this test, you will be able to:
- Outline the connection between gender and the prevalence of CAD.
- Discuss gender in relation to the causes of CAD.
- Discuss gender in relation to the diagnosis and treatment of CAD.
1. Which statement about CAD in women is correct?
a. The prevalence of CAD in women decreases from 1 in 3 at ages 45 to 54 to 1 in 8 at ages over 65.
b. CAD is associated with lower morbidity and mortality in women than in men.
c. The prevalence of CAD in women increases from 1 in 12 at ages 45 to 54 to 1 in 8 at ages over 65.
d. The clinical manifestations of CAD in women lag by 10 years compared with those in men.
2. What do women consider to be their greatest health threat?
a. breast cancer
d. cervical cancer
3. What gender-mediated anatomic difference is thought to negatively influence treatment outcomes in women?
a. lower center of gravity in the female body
b. smaller epicardial vessels in women
c. larger internal mammary arteries in women
d. smaller myocardium in women
4. How do women and men differ with regard to presentation of acute coronary events?
a. Men present more frequently with non—ST-elevation myocardial infarction.
b. Women present more frequently with ST-elevation myocardial infarction.
c. Men present more frequently with unstable angina.
d. Women present more frequently with unstable angina.
5. What gender-related difference in CAD pathophysiology is suspected as a mechanism accounting for poorer prognoses for women compared with those for men?
a. Estrogen may be involved in altering plaque stability via inflammatory mechanisms.
b. Testosterone may be involved in altering plaque stability via inflammatory mechanisms.
c. C-reactive protein (CRP) appears to decrease in the presence of increased estrogen levels.
d. High levels of CRP have been shown to have weak prognostic value in both women and men.
6. What is themostsignificant gender-related difference in traditional CAD risk factors?
a. Estrogen, which is associated with greater risk among women than among men.
b. Smoking, which is associated with greater risk among men than among women.
c. Diabetes mellitus, which is associated with greater risk among women than among men.
d. Dyslipidemia, which is associated with greater risk among men than among women.
7. What percentage of women in the United States has impaired glucose tolerance?
a. about 2%
b. about 12%
c. about 32%
d. about 20%
8. Resistance to smoking cessation is linked to
b. decreased CAD risk.
c. improved response to acute coronary syndromes.
d. unstable angina.
9. All of the following circulatory conditions are associated with obesityexcept
a. increases in cardiac preload.
b. increases in cardiac output.
c. expansion of the plasma volume.
d. decreases in stroke volume.
10. Which of the following terms refers to a constellation of the following 5 risk factors: high triglycerides, low high-density lipoprotein cholesterol, high blood pressure, hyperglycemia, and abdominal obesity?
a. metabolic syndrome
b. adult-onset diabetes
c. syndrome X
11. When complaining of chest pain, what symptoms do women typically describe?
a. discomfort centralized over the upper sternum
b. crushing chest pain radiating through the left shoulder and arm
c. burning, squeezing, or upper abdominal fullness, dyspnea, nausea, weakness, cold sweat, dizziness, and fatigue
d. pain, discomfort, or pressure in the chest, collarbone, and neck
12. What are the prospects for noninvasive prevention of CAD in women?
a. There is little evidence that CAD in women is preventable through diet and lifestyle modifications.
b. To date, no primary or secondary CAD prevention trials have focused on women.
c. Primary and secondary CAD prevention trials focusing on women have produced highly inconsistent results.
d. There is strong evidence that CAD in women is largely preventable through diet and lifestyle modifications.
13. For what form of treatment has the use of glycoprotein IIb/IIIa agents produced a similar risk reduction related to cardiac events in men and women?
a. percutaneous transluminal coronary angioplasty with stenting
b. coronary artery bypass graft surgery
c. valve repair and replacement surgery
d. coronary angiography
14. Which of the following isnota bias that has been found in referrals for coronary angiography?
a. Women are less likely to be considered for this diagnostic procedure.
b. Test results are more likely to be positive among women than among men.
c. Women wait longer than men do to go to cardiac angiography.
d. Positive results from 2 stress tests have been required in women, as opposed to just 1 in men.